Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

376 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Publisher Correction: JunB is a key regulator of multiple myeloma bone marrow angiogenesis.
Fan F, Malvestiti S, Vallet S, Lind J, Garcia-Manteiga JM, Morelli E, Jiang Q, Seckinger A, Hose D, Goldschmidt H, Stadlbauer A, Sun C, Mei H, Pecherstorfer M, Bakiri L, Wagner EF, Tonon G, Sattler M, Hu Y, Tassone P, Jaeger D, Podar K. Fan F, et al. Among authors: tassone p. Leukemia. 2021 Dec;35(12):3628. doi: 10.1038/s41375-021-01367-2. Leukemia. 2021. PMID: 34489554 Free PMC article. No abstract available.
Targeting mitochondrial factor Smac/DIABLO as therapy for multiple myeloma (MM).
Chauhan D, Neri P, Velankar M, Podar K, Hideshima T, Fulciniti M, Tassone P, Raje N, Mitsiades C, Mitsiades N, Richardson P, Zawel L, Tran M, Munshi N, Anderson KC. Chauhan D, et al. Among authors: tassone p. Blood. 2007 Feb 1;109(3):1220-7. doi: 10.1182/blood-2006-04-015149. Epub 2006 Oct 10. Blood. 2007. PMID: 17032924 Free PMC article.
p38 mitogen-activated protein kinase inhibitor LY2228820 enhances bortezomib-induced cytotoxicity and inhibits osteoclastogenesis in multiple myeloma; therapeutic implications.
Ishitsuka K, Hideshima T, Neri P, Vallet S, Shiraishi N, Okawa Y, Shen Z, Raje N, Kiziltepe T, Ocio EM, Chauhan D, Tassone P, Munshi N, Campbell RM, Dios AD, Shih C, Starling JJ, Tamura K, Anderson KC. Ishitsuka K, et al. Among authors: tassone p. Br J Haematol. 2008 May;141(5):598-606. doi: 10.1111/j.1365-2141.2008.07044.x. Epub 2008 Apr 7. Br J Haematol. 2008. PMID: 18397345 Free article.
Molecular targets for the treatment of multiple myeloma.
Rossi M, Di Martino MT, Morelli E, Leotta M, Rizzo A, Grimaldi A, Misso G, Tassone P, Caraglia M. Rossi M, et al. Among authors: tassone p. Curr Cancer Drug Targets. 2012 Sep;12(7):757-67. doi: 10.2174/156800912802429300. Curr Cancer Drug Targets. 2012. PMID: 22671925 Review.
Targeting miR-21 inhibits in vitro and in vivo multiple myeloma cell growth.
Leone E, Morelli E, Di Martino MT, Amodio N, Foresta U, Gullà A, Rossi M, Neri A, Giordano A, Munshi NC, Anderson KC, Tagliaferri P, Tassone P. Leone E, et al. Among authors: tassone p. Clin Cancer Res. 2013 Apr 15;19(8):2096-106. doi: 10.1158/1078-0432.CCR-12-3325. Epub 2013 Feb 27. Clin Cancer Res. 2013. PMID: 23446999 Free PMC article.
Inhibition of miR-21 restores RANKL/OPG ratio in multiple myeloma-derived bone marrow stromal cells and impairs the resorbing activity of mature osteoclasts.
Pitari MR, Rossi M, Amodio N, Botta C, Morelli E, Federico C, Gullà A, Caracciolo D, Di Martino MT, Arbitrio M, Giordano A, Tagliaferri P, Tassone P. Pitari MR, et al. Among authors: tassone p. Oncotarget. 2015 Sep 29;6(29):27343-58. doi: 10.18632/oncotarget.4398. Oncotarget. 2015. PMID: 26160841 Free PMC article.
Disentangling the microRNA regulatory milieu in multiple myeloma: integrative genomics analysis outlines mixed miRNA-TF circuits and pathway-derived networks modulated in t(4;14) patients.
Calura E, Bisognin A, Manzoni M, Todoerti K, Taiana E, Sales G, Morgan GJ, Tonon G, Amodio N, Tassone P, Neri A, Agnelli L, Romualdi C, Bortoluzzi S. Calura E, et al. Among authors: tassone p. Oncotarget. 2016 Jan 19;7(3):2367-78. doi: 10.18632/oncotarget.6151. Oncotarget. 2016. PMID: 26496024 Free PMC article.
Drugging the lncRNA MALAT1 via LNA gapmeR ASO inhibits gene expression of proteasome subunits and triggers anti-multiple myeloma activity.
Amodio N, Stamato MA, Juli G, Morelli E, Fulciniti M, Manzoni M, Taiana E, Agnelli L, Cantafio MEG, Romeo E, Raimondi L, Caracciolo D, Zuccalà V, Rossi M, Neri A, Munshi NC, Tagliaferri P, Tassone P. Amodio N, et al. Among authors: tassone p. Leukemia. 2018 Sep;32(9):1948-1957. doi: 10.1038/s41375-018-0067-3. Epub 2018 Feb 22. Leukemia. 2018. PMID: 29487387 Free PMC article.
miR-22 suppresses DNA ligase III addiction in multiple myeloma.
Caracciolo D, Di Martino MT, Amodio N, Morelli E, Montesano M, Botta C, Scionti F, Talarico D, Altomare E, Gallo Cantafio ME, Zuccalà V, Maltese L, Todoerti K, Rossi M, Arbitrio M, Neri A, Tagliaferri P, Tassone P. Caracciolo D, et al. Among authors: tassone p. Leukemia. 2019 Feb;33(2):487-498. doi: 10.1038/s41375-018-0238-2. Epub 2018 Aug 17. Leukemia. 2019. PMID: 30120376 Free PMC article.
376 results